InflaRx N.V. (IFRX) Stock

InflaRx N.V. (IFRX) is a Healthcare stock trading at $1.80 (as of 2026-06-18), with a market capitalization of $158.68M and a trailing P/E of -2.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

InflaRx N.V. is a clinical-stage biopharmaceutical company that discovers and develops C5a-related inhibitors to address inflammatory and autoimmune diseases. Its pipeline includes vilobelimab (an anti-C5a monoclonal antibody in clinical development), INF904 (an oral small-molecule candidate), and IFX002, with programs conducted primarily in Germany and the United States.

Valuation — source: SEC EDGAR (first-party)
Price	$1.80
Market Cap	$158.68M
P/E Ratio	-2.7
Price / Book	3.15
Price / Sales	4461.15
DCF Value (model)	$-8.30
DCF Upside vs Price	-559.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$29331.00
Net Margin	-155582.1%
Return on Equity	-109.8%
Current Ratio	4.13
Revenue Growth (YoY)	-82.3%
EPS Growth (YoY)	-12.8%

Valuation vs Sector & Industry
Stock P/E	-2.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-112.7%
vs Industry	-115.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($7.10M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Niels C. Riedemann
Employees	74
Country	DE
IPO Date	2017-11-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.